NCT06293053招募中3 期
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Sanofi
- 入组人数
- 18
- 试验地点
- 19
- 主要终点
- Concentration of dupilumab in serum
研究概览
简要总结
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.
The study consists of 3 periods:
- Screening period: 2 to 4 weeks.
- Treatment period: 24 weeks.
- Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).
The total number of planned study visits for each participant will be 6.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be ≥6 months to <18 years of age, at the time of signing the informed consent.
- •A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of ≥2 with presence of ≥6 pruriginous lesions at Baseline. The lesions should be present on ≥2 different body surface areas at Baseline.
- •On the worst itch numerical rating scale (WI-NRS) (for participants aged ≥6 years to <18 years old at the screening visit) or worst-scratch/itch NRS (for participants aged ≥6 months to <6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of ≥7 in the 7 days prior to Day
- •NOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1/Baseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.
- •Participants/Caregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study.
- •Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Presence of active moderate to severe lesions of atopic dermatitis (AD), and/or other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease.
- •Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.
- •NOTE: Participants may be rescreened after infection resolves.
- •Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
- •Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
- •Planned or anticipated major surgical procedure during the participant's participation in this clinical trial.
- •Participants who has taken biologic therapy/systemic immunosuppressant/ immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer.
- •Current participation to any clinical trial of an investigational drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer.
- •Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.
研究组 & 干预措施
Dupilumab
Experimental
Administered subcutaneously (SC) based on weight and age
干预措施: Dupilumab (Drug)
结局指标
主要结局
Concentration of dupilumab in serum
时间窗: Day 1 to Week 40
Concentration of dupilumab in serum over time
次要结局
- Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)(Date of signed ICF (2-4 weeks before Day 1) to Week 40)
- Incidence of anti-drug antibodies (ADA) to dupilumab over time(Day 1 to Week 40)
研究者
研究点 (19)
Loading locations...
相似试验
尚未招募
3 期
An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a PatientsHemophilia A, SevereNCT06738901SK Plasma Co., Ltd.55
进行中（未招募）
3 期
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPompe Disease (Late-onset)NCT03911505Amicus Therapeutics21
已完成
2 期
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsChronic Hepatitis C InfectionNCT02486406AbbVie64
招募中
3 期
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Glycogen Storage Disease Type II Infantile OnsetNCT04808505Amicus Therapeutics36
已完成
3 期
Study of Biostate® in Children With Von Willebrand DiseaseVon Willebrand DiseaseNCT01213446CSL Behring17